Hezkue (Sildenafil)

Hezkue is prescribed for conditions that benefit from increased nitric‑oxide mediated vasodilation. It is commonly used in clinical practice for the following purposes:

• Management of erectile dysfunction in adult males.
• Treatment of pulmonary arterial hypertension to improve exercise capacity.
• Adjunct therapy for certain cases of secondary hypertension where vasodilation is desired.
• Off‑label consideration for Raynaud's phenomenon under specialist supervision.
• Supportive care in selected patients with heart failure-related pulmonary congestion.

• Sildenafil selectively inhibits the enzyme phosphodiesterase type 5, which normally degrades cyclic guanosine monophosphate (cGMP) in smooth muscle cells. By blocking PDE5, sildenafil raises intracellular cGMP levels, leading to relaxation of smooth muscle in the corpus cavernosum and pulmonary vasculature, thereby enhancing blood flow to these tissues when sexual stimulation or pulmonary vascular stress occurs.

Adverse reactions to Hezkue can vary in frequency and severity.

Common

• Headache
• Flushing
• Dyspepsia or indigestion
• Nasal congestion
• Visual disturbances such as a blue tint
• Muscle aches

Serious

• Sudden loss of vision (non‑arteritic anterior ischemic optic neuropathy)
• Sudden hearing loss
• Priapism (prolonged erection lasting more than 4 hours)
• Severe hypotension, especially when combined with nitrates
• Cardiovascular events such as myocardial infarction in high‑risk patients.

Before starting Hezkue, certain health considerations should be reviewed:

• Assess cardiovascular status, especially in patients with recent chest pain or heart attack.
• Evaluate for pre‑existing visual or auditory disorders.
• Review history of priapism or blood‑clotting disorders.
• Consider renal or hepatic impairment, which may affect drug clearance.
• Avoid use in patients taking nitrates or nitric‑oxide donors.
• Counsel patients about the potential for hypotension with alcohol consumption.

Hezkue may interact with several medication classes. Interaction guidance is as follows:

Avoid

• Nitrates (e.g., nitroglycerin, isosorbide dinitrate) due to risk of severe hypotension.
• Guanylate cyclase stimulators (e.g., riociguat) for pulmonary hypertension.
• Certain potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole) that can raise sildenafil levels.

Use with caution

• Alpha‑blockers (e.g., tamsulosin) as they may cause additive blood‑pressure effects.
• Antihypertensive agents, especially when combined with alcohol.
• Other PDE5 inhibitors; concurrent use is contraindicated.
• Medications that affect hepatic metabolism, such as certain antiretrovirals.